Prevalence and correlates of co-infection with human immunodeficiency virus and Hepatitis C virus in male injection drug users in Iran

Archives of Iranian Medicine

Volumn 13, Issue 4, 2010, Pages 318-323

  Hosseini, Mostafa ^a   SeyedAlinaghi, Seyed Ahmad ^b   Kheirandish, Parastoo ^b   Javid, Gholam Reza Esmaeli ^b   Shirzad, Hadi ^c   Karami, Nazli ^b   Jahani, Mohammad Reza ^d   Ahmadian, Mohammad Reza Seyed ^c   Payvarmehr, Fatemeh ^b   Mohraz, Minoo ^b   Koochak, Hamid Emadi ^b   McFarland, Willi ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Research Center   (Iran)

^d Baghiyatallah University   (Iran)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coinfection; HCV; HIV; Injection drug users; Risk factors

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; DRUG ABUSE; DRUG USE; HARM REDUCTION; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHYSICAL EXAMINATION; PRISONER; QUESTIONNAIRE; REHABILITATION CENTER; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; TATTOOING; URINALYSIS; COMPARATIVE STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; HIV INFECTIONS; IRAN; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; IRAN; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 77955495572     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol. 2008; 23: 1000-1008.
2. Kumar R, Singla V, Kacharya S. Impact and management of hepatitis B and hepatitis C virus coinfection in HIV patients. Trop Gastroenterol. 2008; 29: 136-47.
3. Carmo RA, Guimarães MD, Moura AS, Neiva AM, Versiani JB, Lima LV, et al. The influence of HCV coinfection on clinical, immunological, and virological responses to HAART in HIV-patients. Braz J Infect Dis. 2008; 12: 173-179.
4. Roe B, Hall WW. Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev Mol Med. 2008; 10: e30.
5. Monto A, Currie S, Wright TL. Liver disease in injection drug users with hepatitis C, with and without HIV coinfection. J Addict Dis. 2008; 27: 49-59.
6. Low E, Vogel M, Rockstroh J, Nelson M. Acute hepatitis C in HIV-positive individuals. AIDS Rev. 2008; 10: 245-253.
7. McDonald SA, Donaghy M, Goldberg DJ, Hutchinson S, Robertson C, Bird S, et al. A populationbased record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res. 2009; 18: 271-283.
8. Lo Re V, Kostman JR, Amorosa VK. Management complexities of HIV/hepatitis C virus coinfection in the twenty-_rst century. Clin Liver Dis. 2008; 12: 587-609.
9. Solomon S, Srikrishnan A, Mehta S, Vasudevan C, Murugavel K, Thamburaj E, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. JAIDS. 2008; 49: 327-332.
10. Catalan-Soares BC, Almeida RTP, Carneiro-Proietti ABF. Prevalence of HIV-1/2, HTLV-I/II, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum, and Trypanosoma cruzi among prison inmates at Manhuacu, Minas Gerais State, Brazil. Rev Soc Bras Med Trop. 2000; 33: 27-30.
11. Haber PS, Parsons SJ, Harper SE, White PA, Rawlinson WD, Lloyd AR. Transmission of hepatitis C within Australian prisons. Med J Aust. 1999; 171: 31-33.
12. Mutter RC, Grimes RM, Labarthe D. Evidence of intraprison spread of HIV infection. Arch Intern Med.1994; 154: 793-795.
13. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol. 1997; 26: 1359-1366.
14. Pontali E, Ferrari F. Prevalence of hepatitis B virus and/or hepatitis C virus coinfections in prisoners infected with the human immunodeficiency virus. Int J Prison Health. 2008; 4: 77-82.
15. Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Quaye IKE, Hesse IFA, et al. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis among prison inmates and officers at Nsawam and Accra, Ghana. J Med Microbiol. 2006; 55: 593-597.
16. Re V, Gallego S, Farías A, Barbás G, Kremer L, Díaz MP, et al. Hepatitis C and HIV coinfection in central region of Argentina: prevalence, genotype characterization, and risk factors. Enferm Infecc Microbiol Clin. 2008; 26: 423-425.17.
17. Sabbatani S, Giuliani R, Fulgaro C, Paolillo P, Baldi E, Chiodo F. HIVAb, HCVAb, and HBsAg seroprevalence among inmates of the prison of Bologna and the effect of counselling on the compliance of proposed tests. Epidemiol Prev. 2004; 28: 163-168.
18. Sáiz de la Hoya P, Bedia M, Murcia J, Cebriá J, Sánchez-Payá J, Portilla J. Predictive markers of HIV and HCV infection and coinfection among inmates in a Spanish prison. Enferm Infecc Microbiol Clin. 2005; 23: 53-57.
19. Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis B virus, and hepatitis C virus infections in drug addicts among Zanjan prisoners. Arch Iran Med. 2003; 6: 1-4.
20. Massad E, Rozman M, Azevedo RS. Seroprevalence of HIV, HCV, and syphilis in Brazilian prisoners: preponderance of parenteral transmission. Eur J Epidemiol. 1999; 15: 439-445.
21. Skoretz S, Zaniewski G, Goedhuis NJ. Hepatitis C virus transmission in the prison/inmate population. Can Commun Dis Report. 2004; 30: 16-26.
22. Mirahmadizadeh AR, Kadivar MR, Hemmati AR, Javadi A. Infection with HIV and hepatitis C, and B viruses among injecting drug users in Shiraz, Southern Iran. 15th International Conference on AIDS; Bangkok, Thailand. 11-12 July, 2004;
23. Aminzadeh Z, Aghazadeh Sarhangi K. Seroepidemiology of HIV, syphilis, hepatitis B, and C in intravenous drug users at Loghman Hakim hospital. IJMM. 2008; 1: 53-56.
24. Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B, and hepatitis C coinfection in Kenya. AIDS. 2008; 22: 1221-1222.
25. Rodrigues MCV, Viotti JB, Braga RF, Lourenco LFS, Antunes CMF, Lambertucci JR. HIV/HCV coinfection in infectious disease units in Mozambique and Brazil: a comparative study. Revista da Sociedade Brasileira de Medicina Tropical. 2008; 41: 518.
26. March JC, Oviedo-Joekes E, Romero M. Factors associated with reported hepatitis C and HIV among injecting drug users in ten European cities. Enferm Infecc Microbiol Clin. 2007; 25: 91-97.
27. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS. 2005; 19: 709-716.
28. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. 2006; 3: 12.
29. Manavi M, Baghestanian M, Watkins-Riedel T, Battistutti W, Pischinger K, Schatten C, et al. Detection of hepatitis C virus (HCV) RNA in normal cervical smears of HCV-seropositive patients. Clin Infect Dis. 2002; 35: 966-973.
30. Hajiabdolbaghi M, Razani N, Karami N, Kheirandish P, Mohraz M, Rasoolinejad M, et al. Insights from a survey of sexual behavior among a group of at-risk women in Tehran, Iran, 2006. AIDS Educ Prev. 2007; 19: 519-530.
31. UNAIDS Update 2004. Islamic Republic of Iran: Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Disease. Available from: URL: http://data.unaids.org/Publications/Fact-Sheets01/iran_en.pdf?preview=true (Accessed 12 May 2005 and 7 January 2007)
32. Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iran Med. 2002; 5: 184-190.